GWAS · Primary T cells · Mechanistic genetics
MCCv maps noncoding GWAS variants to genes; neo-CTCF at SESN3 raises autoimmune risk
MCCv maps noncoding GWAS variants to genes in primary CD4+ T cells and, at rs4409785, shows a disease-associated
allele creating a neo-CTCF motif that cuts SESN3 and is tied to autoimmune risk. Base editing is used to test
that mechanism. This is a research method, not a therapy.
Caveat: Research platform and mechanistic genetics, not a therapy or a clinical diagnostic. Drug-repurposing implications are exploratory. Competing interests are disclosed (Nucleome Therapeutics / BEAM shares for some authors).
Nature Genetics →
CRISPR · Mouse · Spatiotemporal control
Photoswitchable Cas12f plus focused ultrasound edits genes only in targeted mouse tissues
Song et al. report non-invasive spatiotemporal control of gene editing in vivo. A photoswitchable Cas12f, delivered
with its guide RNA in one AAV, is switched on by external light. Focused ultrasound drives mechanoluminescent
particles that make local light deep in tissue, so edits are limited to targeted skeletal muscle and brain regions
in mice. Nature’s research highlight is dated October 2, 2026; the primary paper is in Cell.
Caveat: Preclinical mouse work. Not a human therapy. Safety, the off-target profile, and clinical delivery remain open.
Nature Research Highlight →
Cell →
Alzheimer disease · Immune eQTLs · In silico
Single-cell genetics prioritizes immune genes and exploratory drug-repurposing hypotheses in Alzheimer’s disease
An npj Aging paper published October 2, 2026 integrates immune cell–specific cis-eQTLs from OneK1K with Alzheimer’s
disease GWAS, using Mendelian randomization and colocalization. It prioritizes naïve and central-memory T-cell
and monocyte contexts and candidate genes, including KANSL1-AS1, CTSH, FCER1G, EPHA1-AS1, CRHR1, and JAZF1, then
offers exploratory compound–gene repurposing hypotheses after blood-brain-barrier and docking filters.
Caveat: Genetic prioritization and in silico hypotheses only. They require experimental and clinical validation. Not treatment guidance.
npj Aging →
Transplant · Epigenetic age · Preprint
Grafted hearts’ epigenetic age shifts toward the host (mice + human biopsies); preprint
Poganik et al., in a bioRxiv preprint covered by Nature News on September 28, 2026, find that a donor heart’s
DNA-methylation age moves toward the recipient’s age in mouse heterotopic grafts and in selected human transplant
biopsies with large donor–recipient age gaps. Some functional measures one year after transplant tracked recipient
age more than donor age. The authors suggest donor pools might eventually expand if older grafts can rejuvenate
in younger hosts. That suggestion is still hypothesis-level.
Caveat: Preprint, not peer-reviewed. The human biopsy set with large age gaps is small (n=11). This is not a change to transplant guidelines. Some functional traits may be irreversible. “Rejuvenate” here is the authors’ suggestion, not a proven effect.
Nature News →
bioRxiv preprint →
